NEW YORK, September 25, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Celgene Corporation (NASDAQ: CELG), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC), and BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Vertex Pharmaceuticals Incorporated Research Report
On September 3, 2013, Vertex Pharmaceutical Inc. (Vertex) announced that five abstracts from its Cystic Fibrosis (CF) research and development program will be presented at the 27th Annual North American Cystic Fibrosis Conference (NACFC) in Salt Lake City, Utah between October 17 and October 19, 2013. Vertex informed that data from a Phase 3 study of ivacaftor in non-G551D gating mutations will be presented as well as long-term safety and efficacy data for KALYDECO™ (ivacaftor) from the PERSIST open-label rollover study. Fred Van Goor, Ph.D., Head of Biology for Vertex's CF program, and David Rodman, M.D., Vice President of Clinical Development for Vertex's CF program, will participate in invited talks regarding their work to discover and develop medicines that target the underlying cause of CF. The Full Research Report on Vertex Pharmaceuticals Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/e696_VRTX]
Celgene Corporation Research Report
On September 6, 2013, Celgene Corp. (Celgene) announced that the Company has received an approval from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) of ABRAXANE, as first-line treatment for patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine. Jean-Pierre Bizzari, M.D., Executive Vice President of Hematology and Oncology for Celgene Corporation commented, "The addition of ABRAXANE to gemcitabine demonstrated meaningful improvements across key efficacy outcomes, including overall survival, with a well-characterized safety profile." The Full Research Report on Celgene Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/7f47_CELG]
NPS Pharmaceuticals, Inc. Research Report
On September 10, 2013, NPS Pharmaceuticals, Inc. (NPS Pharmaceuticals) announced the appointment of President and CEO Francois Nader, M.D. to the Biotechnology Industry Organization's (BIO's) Board of Directors as a member of the Health Section Governing Board. The Company said that BIO is the world's largest biotechnology trade association and represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. "It's a pleasure to serve on the BIO board alongside many of the biotechnology industry's leading executives," said Dr. Nader. "I share BIO's commitment to promoting biomedical innovation and finding ways to reduce hurdles to life-saving therapies." The Full Research Report on NPS Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/441a_NPSP]
Cyclacel Pharmaceuticals, Inc. Research Report
On September 19, 2013, Cyclacel Pharmaceuticals, Inc. (Cyclacel) provided updated data showing that Sapacitabine, an orally-available nucleoside analogue, has activity against a majority of ovarian cancer samples taken from patients, including resistant tumors. "We are encouraged by the activity signal of sapacitabine in ovarian cancer samples," said Judy Chiao, M.D., Vice President, Clinical Development and Regulatory Affairs of Cyclacel. "This observation may be directly related to the drug's mechanism which is enhanced in cancer cells with reduced capacity for DNA repair through the homologous recombination repair or HR pathway." According to Cyclacel, the reported data further support the potential for sapacitabine to be used as a treatment for HR defective cancers, such as ATM- or BRCA-defective tumors. The Company also informed that clinical trials examining the activity of sapacitabine in ATM-defective CLL, and of sapacitabine in combination with Cyclacel's seliciclib in cancer patients with BRCA1 or BRCA2 mutations, are currently in progress. The Full Research Report on Cyclacel Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/fa88_CYCC]
BioCryst Pharmaceuticals, Inc. Research Report
On September 17, 2013, BioCryst Pharmaceuticals, Inc. (BioCryst) announced that it has been awarded a contract by the National Institute of Allergy and Infectious Diseases (NIAID) to develop BCX4430 as a treatment for Marburg virus disease. NIAID, which is a part of the National Institutes of Health has made an initial award of $5.0 million to BioCryst. According to BioCryst, the contract aims to file investigational new drug (IND) applications for intravenous (i.v.) and intramuscular (i.m.) BCX4430 for the treatment of Marburg virus disease, and to conduct an initial Phase 1 human clinical trial. Also, as per the Company, the contract supports the appropriate IND-enabling program and the initial clinical trial. The Full Research Report on BioCryst Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/f9b1_BCRX]
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner